Imatinib Discontinuation in Chronic Phase CML Doesn’t Always Lead to Relapse
Almost half of patients with chronic-phase chronic myeloid leukemia (CML) who discontinued imatinib treatment did not relapse, according to results of a prospective study. Those who did relapse showed continued sensitivity to imatinib when treatment started again.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Leukemia | Study